GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » Valuation Rank

Vifor Pharma AG (LTS:0RPD) Valuation Rank


View and export this data going back to 2014. Start your Free Trial

What is Vifor Pharma AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Vifor Pharma AG Valuation Rank Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Vifor Pharma AG (LTS:0RPD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » Valuation Rank
Comparable Companies
XSWX:SFZN XSWX:PPGN XTER:MRK ZTS TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 VTRS SHSE:600196 NBIX NSE:DIVISLAB SZSE:000963 HKSE:03692 XTAE:TEVA SZSE:000661 SZSE:300142 SHSE:600085
Traded in Other Exchanges
N/A
Address
Rechenstrasse 37, Saint Gallen, CHE, 9014
Website
https://www.viforpharma.com
Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.